register

News & Trends - MedTech & Diagnostics

Increased access to specialist heart procedure for AF patients

Health Industry Hub | August 8, 2022 |

MedTech News: A clinical partnership in Australia is offering advanced surgical ablation for more difficult atrial fibrillation (AF) cases.

Hollywood Private Hospital is set to become a training and education hub in Australasia for the specialist heart procedure Hybrid Catheter Ablation and Surgical Ablation (HyCASA).

Cardiothoracic Surgeon Pragnesh Joshi and Cardiac Electrophysiologist Rukshen Weerasooriya are the only practitioners performing HyCASA in the southern hemisphere and are expected to train 12 teams in the next 18 months. The first team to train were clinicians from Peninsula Private Hospital and Monash Medical Centre in Melbourne.

HyCASA is a keyhole minimally invasive surgery performed on a beating heart. It is for patients with long-standing persistent atrial fibrillation (AF or Afib). Atrial fibrillation is an abnormal heart rhythm caused by erratic electrical signals in the heart, and affects about 2% of the Australian population.

The aim of HyCASA is to interrupt the atrial fibrillation circuits and return the heart back to a normal rhythm. It combines endocardial radiofrequency ablation (which treats the inside of the heart) with epicardial ablation (which treats the outside of the heart) using Atricure’s AtriClip PRO2 implantable clip which is sponsored by AA-Med in Australia.

Prof Weerasooriya said a comprehensive HyCASA training program is important to provide AF patients with increased access to the specialist procedure across Australia, New Zealand and the Asia Pacific.

“All participants need to be fully briefed on a new procedure for optimal outcomes for the patient,” Prof Weerasooriya said.

Hollywood is one of the busiest providers of HyCASA outside of the US, with more than 80 patients treated in the past three years. The experiences and outcomes from the Hollywood team will be delivered via podium presentations at Australian and international clinical conferences.

Most patients considered for HyCASA have persistent AF or previous procedures have not been effective. It is estimated almost half of AF patients have long-standing and persistent AF.

The CONVERGE clinical trial found the hybrid AF procedure had superior effectiveness compared to endocardial catheter ablation (CA) alone for the treatment of persistent atrial fibrillation. 

Hearts4Heart CEO Tanya Hall said HyCASA provides an important alternative for patients when other therapies have failed.

“These are the patients with the most debilitating levels of atrial fibrillation where no other therapy has proven successful,” Ms Hall said.

“Given atrial fibrillation is a growing epidemic in Australia patient access to HyCASA is essential. We would like to see more surgeons being trained in HyCASA so that it is accessible for all patients, in all states across Australia.”

Hollywood Private Hospital CEO Andrew Tome said it is the mission of Hollywood to offer new and innovative therapies for patients who have had limited options in the past.

“We are proud to support specialists in their clinical research and technique development,” Mr Tome said.

Atrial fibrillation increases the risk of stroke, heart failure, chronic fatigue, decreased activity levels and a diminished quality of life. In 2017-18, atrial fibrillation accounted for more than 72,000 hospitalisations in Australia and 9% of deaths were associated with the condition in 2018.

The Health Industry Hub content is copyright protected and access is provided under individual user licenses. For more information, click here and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Aussie medtech forges ahead, making inroads with new technology

Aussie medtech forges ahead, making inroads with new technology

Health Industry Hub | February 23, 2024 |

MedTech & Diagnostics News: Adelaide-based medical technology firm, LBT Innovations has successfully delivered its cutting-edge Automated Plate Assessment System (APAS) […]

More


News & Trends - Pharmaceuticals

Is the imposed PBS funding cap driving the migraine medicines shortage?

Is the imposed PBS funding cap driving the migraine medicines shortage?

Health Industry Hub | February 23, 2024 |

Pharma News: Australia finds itself grappling with an unparalleled shortage of migraine prevention medicines, leaving a significant impact on the […]

More


News & Trends - Pharmaceuticals

MSAC rejects Janssen's CAR T therapy despite clinical superiority, citing need for 'substantial price reduction'

MSAC rejects Janssen’s CAR T therapy despite clinical superiority, citing need for ‘substantial price reduction’

Health Industry Hub | February 23, 2024 |

Pharma News: The Medical Services Advisory Committee (MSAC) has deferred its decision on whether Janssen’s CAR T-cell therapy Carvykti (cilta-cel) […]

More


News & Trends - Pharmaceuticals

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Health Industry Hub | February 23, 2024 |

Pharma News: The Therapeutic Goods Administration (TGA) has granted approval for the first endometriosis treatment in 13 years. Gedeon Richter […]

More


This content is copyright protected. Please subscribe to gain access.